Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.67 |
| ▸ | PRKACA | P17612 | 2/20 | 0.67 |
| ▸ | PRKX | P51817 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.67 |
| ▸ | GRK5 | P34947 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213922 | 0.89 | MMP13 (0.54) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL5210079 | 0.88 | RAB9A (0.60) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL5212711 | 0.86 | RAB9A (0.67) | MMP13ROCK2CYP3A4CYP2C9HPGD | |
| SCHEMBL5213931 | 0.86 | ROCK2 (0.54) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL5213531 | 0.85 | ROCK2 (0.69) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL1568252 | 0.85 | ROCK2 (0.86) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL8358822 | 0.85 | MMP13 (0.69) | MMP13ROCK2ROCK1PRKACAPRKX | |
| SCHEMBL9416645 | 0.84 | MMP13 (0.94) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL31061610 | 0.84 | MMP13 (1.00) | MMP13AURKAROCK2ROCK1PRKACA | |
| SCHEMBL5332068 | 0.84 | MMP13 (1.00) | MMP13AURKAROCK2ROCK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1455790-B1 | USE OF PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND OF PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES FOR SELECTIVE COLLAGENASE INHIBITION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003049738-A1 | USE OF PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND OF PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES FOR SELECTIVE COLLAGENASE INHIBITION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | WO | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885AURKA 3986/4885ROCK2 449/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | MMP13 1/4885AURKA 3842/4885ROCK2 1398/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | MMP13 1/4885AURKA 3887/4885ROCK2 1264/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885AURKA 4198/4885ROCK2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.